Survival outcomes in patients with and without CNS involvement. Of the initial 31 patients with CNS B-ALL who received infusion, 8 patients died during a median follow-up of 13.8 months. (A) PFS and (B) OS are shown. No statistically significant differences were noted between the outcomes in patients with and without CNS disease.